These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32231703)

  • 1. An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.
    Mujer MTP; Rai MP; Atti V; Dimaandal IL; Chan AS; Shrotriya S; Gundabolu K; Dhakal P
    Adv Hematol; 2020; 2020():7636104. PubMed ID: 32231703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT.
    Wojtowicz D; Tomaszuk-Kazberuk A; Małyszko J; Koziński M
    Wiad Lek; 2020; 73(11):2528-2534. PubMed ID: 33454696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bleeding in patients receiving non-vitamin K antagonists.
    Balla S; Koerber S; Flaker G
    Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who, when, and how to reverse non-vitamin K oral anticoagulants.
    Aronis KN; Hylek EM
    J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
    Brown KS; Zahir H; Grosso MA; Lanz HJ; Mercuri MF; Levy JH
    Crit Care; 2016 Sep; 20(1):273. PubMed ID: 27659071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of agents for reversing the effects of target-specific oral anticoagulants.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Douglas JS
    Am J Health Syst Pharm; 2017 Jan; 74(2):54-61. PubMed ID: 27895055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants.
    Andresen K; Atar D; Gjertsen E; Ghanima W; Roseth S; Johansen OE
    Scand Cardiovasc J; 2018 Jun; 52(3):156-162. PubMed ID: 29569500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm.
    Palaiodimos L; Miles J; Kokkinidis DG; Barkolias C; Jonnalagadda AK; Papaconstantinou D; Frountzas M; Misiakos EP; Schizas D
    Curr Pharm Des; 2018; 24(38):4540-4553. PubMed ID: 30585542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative management of patients receiving non-vitamin K antagonist oral anticoagulants: up-to-date recommendations.
    Kim KS; Song JW; Soh S; Kwak YL; Shim JK
    Anesth Pain Med (Seoul); 2020 Apr; 15(2):133-142. PubMed ID: 33329805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.